{"id":7442,"date":"2025-10-06T11:01:26","date_gmt":"2025-10-06T05:31:26","guid":{"rendered":"https:\/\/lakshmishree.com\/news\/?p=7442"},"modified":"2025-10-08T13:08:42","modified_gmt":"2025-10-08T07:38:42","slug":"details-of-rubicon-research-ipo","status":"publish","type":"post","link":"https:\/\/lakshmishree.com\/news\/details-of-rubicon-research-ipo\/","title":{"rendered":"Details of Rubicon Research Limited IPO : Lot Size, Check Issue Date, Price"},"content":{"rendered":"\n

Rubicon Research<\/strong><\/strong> IPO Price: <\/strong>\u20b9461 to \u20b9485 per share
IPO Dates:<\/strong> 9th October 2025 – 13th October 2025<\/p>\n\n\n\n

\n
\n
\n
\n
\"Rubicon<\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Company Overview<\/strong><\/h2>\n\n\n\n

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in developing, manufacturing, and commercializing differentiated formulations for global markets.<\/p>\n<\/div>\n<\/div>\n\n\n\n

Business Overview<\/strong><\/h2>\n\n\n\n

As of June 30, 2025, Rubicon Research has built a robust portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. Out of these, 66 products are already commercialized, contributing significantly to the US generic pharmaceutical market valued at USD 2,455.7 million, with Rubicon\u2019s own contribution standing at USD 195 million in Fiscal 2024.<\/p>\n\n\n\n

Product Pipeline and Development<\/h2>\n\n\n\n

The company continues to strengthen its pipeline, with 17 new products awaiting US FDA ANDA approval and 63 others at various stages of development. This reflects Rubicon\u2019s strong research focus and consistent investment in innovation.<\/p>\n\n\n\n

Global Presence and Distribution<\/h2>\n\n\n\n

As of June 30, 2025, Rubicon marketed over 350 SKUs to 96 customers, including three major wholesalers who together account for more than 90% of wholesale drug distribution in the United States. The company also caters to group purchasing organizations (GPOs), national and regional pharmacy chains, and managed care organizations. Beyond the US, Rubicon has registered or filed 48 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates, and plans to begin commercial operations in these regions upon approval. Additionally, Rubicon provides contract manufacturing services to customers in India, Australia, and New Zealand.<\/p>\n\n\n\n

Infrastructure and Facilities<\/h2>\n\n\n\n

Rubicon Research operates three state-of-the-art manufacturing facilities in India and two US FDA-inspected R&D centers located in India and Canada, ensuring global quality standards and regulatory compliance.<\/p>\n\n\n\n

Competitive Strengths<\/h2>\n\n\n\n